HMGA1 and hypoparathyroidism-retardation-dysmorphism syndrome: Given that olaparib is clinically used to treat cancers with HRD, including ovarian and EC, we examined the sensitivity of HMGA1 to olaparib in HRD ovarian cancer cells.